

## Special Issue

# Innovative Therapeutic Strategies and Molecular Mechanisms in Breast Cancer

### Message from the Guest Editors

Breast cancer remains one of the most prevalent and complex malignancies worldwide, accounting for a significant proportion of cancer-related morbidity and mortality among women. Advances in molecular biology have unraveled the heterogeneity of breast cancer, revealing diverse subtypes characterized by distinct genetic and molecular profiles. Understanding these molecular mechanisms has paved the way for the development of targeted therapies, which have markedly improved patient outcomes. However, resistance to current treatments and metastatic progression continue to pose major challenges, necessitating innovative therapeutic strategies.

This Special Issue aims to provide a comprehensive overview of innovative approaches—from molecular targets and signaling pathways to emerging treatment modalities—that address the unmet needs in breast cancer therapy.

We look forward to receiving your valuable contributions to advance the understanding and treatment of breast cancer through this special collection.

---

### Guest Editors

Dr. Oana Gabriela Trifanescu

The Clinical Department, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania

Dr. Laurentia Nicoleta Gales

1. "Prof. Dr. Alexandru Trestioreanu" Oncology and Palliative care Discipline, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania
2. Medical Oncology II Department, "Prof. Dr. Alexandru Trestioreanu" Oncology Institute, 022328 Bucharest, Romania

---

### Deadline for manuscript submissions

30 April 2026



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/252311](https://mdpi.com/si/252311)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLUS / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).